Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal C...(nts who received doses up to6 mg: --...),Health

-- There were no serious adverse events related to Cethrin.

-- The data from 6 and 12 months showed 38% (5 of 13) of cervical injury

patients showed a 2-grade or better AIS grade improvement.

-- Subgroup analysis appears to indicate a dose related response in the

cervical patient group with 43% (3 of 7) of the cervical patients from

the 1 and 3 mg dose groups demonstrating improvement of at least 2 AIS

grades. Two of these three patients improved 3 levels from AIS grade A

to AIS grade D.

-- Subgroup analysis of 12-month mean motor score changes showed

improvement in both the 1 and 3 mg dosage groups in the

cervical-injured patients with mean motor score changes of 16.3 points

in the 1 mg and 27.3 points in the 3 mg doses.

-- Analysis of individual dose groups over time using both ASIA Impairment

Scale grade and ASIA Motor Score changes suggest that the most

effective Cethrin doses are 1 and 3 mg for cervical patients.

Patients in the cervical and thoracic 9 mg dose cohort are still being assessed and their data will be reported when it is available.

About Cethrin(R)

Cethrin is a recombinant protein drug that is being investigated for its potential to restore motor and sensory function after spinal cord injury. Following an SCI, about two-thirds of patients undergo decompression/stabilization surgery. During surgery, Cethrin is delivered by a single application to the injured region of the spinal cord. Cethrin has been designated as an Orphan Drug by the FDA.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Co
'/>"/>